PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR)
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PREDATOR
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 09 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 26 Sep 2018 New trial record